Contact a distributor
ATryn is available through the following authorized distributors. Please contact a vendor directly to place your order.
- ABO Pharmaceuticals
- 7930 Arjons Drive, Suite A
- San Diego, CA 92126
- ASD Healthcare
- 3101 Gaylord Parkway, 3rd Floor
- Frisco, TX 75034
- BDI Pharma
- 120 Research Drive
- Columbia, SC 29203
- 2826 South Potter Road
- Tempe, AZ 85282
- Bloodcenter of Wisconsin
- 638 N. 18th Street
- Milwaukee, WI 53201
- Cardinal Health SPD
- 305 Tech Park Drive
- Suite 113
- La Vergne, TN 37086
- FFF Enterprises, Inc.
- 41093 County Center Drive
- Temecula, CA 92591
- McKesson Plasma and BioLogics, LLC
- 401 Mason Road
- La Vergne, TN 37086
- Prodigy Health Supplier
- 9417 Brodie Lane
- Austin, TX 78748
Ready when you need it
- ATryn is a sterile, lyophilized powder; each single-use vial contains the potency stated on the label, which is approximately 525 IU or 1750 IU1
- Store ATryn refrigerated between 2°C and 8°C (36°F and 46°F)1
References: 1. ATryn [package insert] Framingham, MA: rEVO Biologics, December 2013.
Indications and Usage
ATryn is a recombinant antithrombin indicated for the prevention of peri-operative and peri-partum thromboembolic events in hereditary antithrombin deficient patients.
It is not indicated for treatment of thromboembolic events in hereditary antithrombin deficient patients.
Important Safety Information
ATryn is contraindicated in patients with known hypersensitivity to goat and goat milk proteins. Allergic-type hypersensitivity reactions, including anaphylaxis, are possible. Patients must be closely monitored and carefully observed for any symptoms throughout the infusion period. Patients should be informed of the early signs of hypersensitivity reactions including hives, generalized urticaria, tightness of the chest, wheezing, hypotension, and anaphylaxis. If these symptoms occur during administration, treatment must be discontinued immediately and emergency treatment should be administered.
The anticoagulant effect of drugs that use antithrombin to exert their anticoagulation may be altered when ATryn is added or withdrawn. To avoid excessive or insufficient anticoagulation, coagulation tests suitable for the anticoagulant used (e.g., aPTT and anti-Factor Xa activity) are to be performed regularly, at close intervals, and in particular in the first hours following the start or withdrawal of ATryn. Additionally, patients should be monitored for the occurrence of bleeding or thrombosis in such situations.
The serious adverse reaction that has been reported in clinical studies is hemorrhage (intra-abdominal, hemarthrosis, and post procedural). The most common adverse events reported in clinical trials at a frequency of
≥ 5% are hemorrhage and infusion site reaction.
For more information, please view full Prescribing Information for ATryn.
To report suspected adverse reactions contact rEVO Biologics at 800-610-3776 or the FDA at 800-FDA-1088 or www.fda.gov/MedWatch.
For more information, please see full Prescribing Information for ATryn.
® ATryn is a registered trademark of rEVO Biologics, Inc.
rEVO Biologics is a registered trademark of LFB S.A.
For medical inquiries, please